Mathematical Modelling of Alternative Pathway of Complement System. 2020

Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
Division of Systems Biomedicine and Pharmacology, LACDR, Leiden University, P.O. Box 9502, 2300 RA, Leiden, The Netherlands. suruchi.bakshi@certara.com.

The complement system (CS) is an integral part of innate immunity and can be activated via three different pathways. The alternative pathway (AP) has a central role in the function of the CS. The AP of complement system is implicated in several human disease pathologies. In the absence of triggers, the AP exists in a time-invariant resting state (physiological steady state). It is capable of rapid, potent and transient activation response upon challenge with a trigger. Previous models of AP have focused on the activation response. In order to understand the molecular machinery necessary for AP activation and regulation of a physiological steady state, we built parsimonious AP models using experimentally supported kinetic parameters. The models further allowed us to test quantitative roles played by negative and positive regulators of the pathway in order to test hypotheses regarding their mechanisms of action, thus providing more insight into the complex regulation of AP.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011414 Properdin A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections. Complement Factor P,Factor P, Complement
D011415 Complement Factor B A glycine-rich, heat-labile serum glycoprotein that contains a component of the C3 CONVERTASE ALTERNATE PATHWAY (C3bBb). Bb, a serine protease, is generated when factor B is cleaved by COMPLEMENT FACTOR D into Ba and Bb. C3 Proactivator,C3PA,Complement 3 Proactivator,Factor B,Properdin Factor B,Bb Fragment of Factor B,Complement Factor B Fragment, Bb,Complement Factor B, Alternative Pathway,Complement Factor B-Derived Fragment Bb,Complement Factor Ba,Complement Factor Bb,Complement Protein B,Complement Protein Factor B,Properdin Factor Ba,Properdin Factor Bb,Properdin Factor Bf,Properdin Factor Bf F1,Bb, Complement Factor,Complement Factor B Derived Fragment Bb,Factor B, Complement,Factor B, Properdin,Factor Ba, Complement,Factor Ba, Properdin,Factor Bb, Complement,Factor Bb, Properdin,Factor Bf, Properdin,Proactivator, C3,Proactivator, Complement 3,Protein B, Complement
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003179 Complement C3b The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g. C3b Complement,C3bi,Complement 3b,Complement Component 3b,Inactivated C3b,iC3b,C3b, Complement,C3b, Inactivated,Complement, C3b,Component 3b, Complement
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017242 Complement Factor H An important soluble regulator of the alternative pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It is a 139-kDa glycoprotein expressed by the liver and secreted into the blood. It binds to COMPLEMENT C3B and makes iC3b (inactivated complement 3b) susceptible to cleavage by COMPLEMENT FACTOR I. Complement factor H also inhibits the association of C3b with COMPLEMENT FACTOR B to form the C3bB proenzyme, and promotes the dissociation of Bb from the C3bBb complex (COMPLEMENT C3 CONVERTASE, ALTERNATIVE PATHWAY). Factor H,Factor H, Complement
D055641 Mathematical Concepts Numeric or quantitative entities, descriptions, properties, relationships, operations, and events. Concept, Mathematical,Concepts, Mathematical,Mathematical Concept

Related Publications

Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
July 1978, Journal of immunology (Baltimore, Md. : 1950),
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
May 1984, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 2007, Advances in experimental medicine and biology,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 1988, Methods in enzymology,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 2016, PloS one,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
December 1983, Pathologie-biologie,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 1985, Developmental and comparative immunology,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 1984, Springer seminars in immunopathology,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
April 2011, Biochimica et biophysica acta,
Suruchi Bakshi, and Fraser Cunningham, and Eva-Maria Nichols, and Marta Biedzka-Sarek, and Jessica Neisen, and Sebastien Petit-Frere, and Christina Bessant, and Loveleena Bansal, and Lambertus A Peletier, and Stefano Zamuner, and Piet H van der Graaf
January 2020, American journal of respiratory and critical care medicine,
Copied contents to your clipboard!